Spyre Therapeutics, Inc. (SYRE) - Dilution Analysis

10-Q filing | 86.8M shares outstanding

10-Q filing | 60.4M shares outstanding

10-Q filing | 60.4M shares outstanding

POS AM filing: This is a post-effective amendment filing to deregister securities from a previous shelf registration statement and sales agreement as the company has terminated all offerings of securities pursuant to the Registration Statement.

10-K filing | 60.3M shares outstanding

S-3 filing: The filing relates to an at-the-market offering of common stock with an aggregate offering price of up to $179,059,869. The company intends to use the net proceeds of the offering to advance clinical programs, develop general infrastructure, and potentially in-license or acquire additional businesses, technologies, products, or assets.

8-K filing: Spyre Therapeutics, Inc. entered into an underwriting agreement for the offer and sale of 7,275,000 shares of common stock at $27.50 per share, with an option for the underwriters to purchase an additional 1,091,250 shares. ($200.0M proceeds)

10-Q filing | 50.9M shares outstanding

S-3 filing: The filing registers for resale by the Selling Stockholders 46,330,799 shares, including shares of Common Stock, shares of Common Stock issuable upon the conversion of Series A Preferred Stock, shares of Common Stock issuable upon the conversion of Series B Preferred Stock and shares of Common Stock issuable upon the exercise of Parapyre Warrants.

S-3 filing: S-3 filing for common stock offering with an aggregate offering price of up to $200,000,000.

10-Q filing | 50.8M shares outstanding

10-Q filing | 36.5M shares outstanding

S-1 filing: This S-1 filing registers for resale up to 22,496,402 shares of Common Stock and 10,865,000 shares of Common Stock issuable upon the conversion of Series B Preferred Stock by selling securityholders.

S-1/A filing: This S-1/A filing registers for resale up to 6,000,000 shares of common stock and 6,000,000 shares of common stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock by selling securityholders.

POS AM filing: This POS AM filing relates to the future sales of shares by existing stockholders and the registration of shares for resale to satisfy obligations under a registration rights agreement.

S-1/A filing: This S-1/A filing registers for resale up to 6,000,000 shares of Common Stock and 6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock by selling securityholders.

POS AM filing: This POS AM filing registers the resale of common stock by existing stockholders, including shares issued upon conversion of Series A Preferred Stock, to satisfy obligations under a registration rights agreement.

POS AM filing: This POS AM filing relates to the resale of common stock by existing stockholders, originally obtained through conversion of preferred stock, and discusses potential dilution and market risks associated with future sales of common stock.

S-1/A filing: This S-1/A filing registers the resale of up to 6,000,000 shares of Common Stock and 6,000,000 shares of Common Stock issuable upon the conversion of 150,000 shares of Series B Preferred Stock by selling stockholders.

10-K filing | 36.2M shares outstanding

S-1/A filing: This S-1/A filing registers the resale of shares of common stock and common stock issuable upon conversion of Series B Preferred Stock by existing stockholders.

S-1 filing: This S-1 filing registers the resale of common stock by selling stockholders, including shares issuable upon conversion of preferred stock. The company will not receive any proceeds from the sale of these shares.

S-1/A filing: This is an S-1/A filing registering the resale of common stock by selling stockholders.

10-Q filing | 4.3M shares outstanding

S-1/A filing: This is an S-1/A filing registering resale shares for selling stockholders.

10-Q filing | 95.6M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale of up to 1,099,284,385 shares of common stock by selling stockholders, consisting of Merger Common Shares, Merger Conversion Shares, and Private Placement Conversion Shares. The company will not receive any proceeds from the sale.

10-Q filing | 65.4M shares outstanding

10-K filing | 65.4M shares outstanding

10-Q filing | 61.5M shares outstanding

10-Q filing | 61.2M shares outstanding

10-Q filing | 50.4M shares outstanding

10-K filing | 49.4M shares outstanding

10-Q filing | 49.3M shares outstanding

10-Q filing | 49.1M shares outstanding

S-3 filing: This prospectus relates to the sale or other disposition from time to time by the selling stockholder named in this prospectus of up to an aggregate of 19,020,434 shares of our common stock.

10-Q filing | 49.0M shares outstanding

10-K filing | 48.0M shares outstanding

10-Q filing | 47.9M shares outstanding

10-Q filing | 44.6M shares outstanding

S-3 filing: Aeglea BioTherapeutics, Inc. may offer up to $400,000,000 aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, subscription rights to purchase common stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination.

10-Q filing | 44.6M shares outstanding

8-K filing: Aeglea BioTherapeutics, Inc. entered into an underwriting agreement to issue and sell 11,652,830 shares of its common stock and pre-funded warrants to purchase 13,610,328 shares of its common stock at a price of $4.75 and $4.7499 respectively.

10-K filing | 29.1M shares outstanding